Project Grant CLSS00000059473

The Louisiana Department of Health (LDH) Office of Behavioral Health received a $54,004,380 Project Grant award from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Opioid STR (CFDA 93.788) program. This 3-year grant, running from September 30, 2024 to September 29, 2027, will enhance existing statewide prevention, treatment, and recovery support services for individuals with or at risk for opioid use disorder (OUD) and/or stimulant use and misuse disorder (SUM)....

The National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, awarded a $267,000 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop "depot formulations" - injectable, subcutaneous drug delivery systems - for opioid painkillers. The goal is to create tamper-resistant and diversion-proof opioid formulations that can provide...

The Department of Justice, Office of Justice Programs, Bureau of Justice Assistance awarded a $1,600,000 Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) Project Grant to the Southern Nevada Health District (SNHD) and sub-recipients Las Vegas Metropolitan Police Department (LVMPD) and University of Nevada, Las Vegas (UNLV). The grant will fund a collaborative initiative to address the opioid crisis in Clark County, Nevada through a public health-focused overdose...

The National Institute on Drug Abuse (NIDA) awarded a $701,959 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Michigan to improve perioperative care for patients with opioid tolerance. The 5-year project aims to: Capture patient-reported opioid use and pain outcomes among opioid-tolerant individuals undergoing common surgical procedures to calibrate current prescribing guidelines. Develop a clinical care pathway for...

This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), particularly those using fentanyl. The key objectives are to: 1) identify barriers to LDI completion through patient, clinician, and system leader interviews; 2) design an enhanced LDI...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will develop novel econometric research designs to integrate real-world evidence (RWE) into the analysis of inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. The $2,542,500 award, effective September 1, 2024 through August 31, 2027, will be administered by the Weill Medical College of Cornell University. The...

This $591,752 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA 93.279 Drug Use and Addiction Research Programs aims to integrate the existing paper-based Opioid and Naloxone Education (ONE) screening tool into a digital platform on tablet PCs. The goal is to improve the ability to consistently deliver screening for opioid risk and provide targeted opioid safety interventions based on individual risk factors. The project will analyze data collected through...

This $297,061 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and testing of a telehealth approach to provide opioid use disorder (OUD) treatment in high-risk settings. The project, titled "RIGHT TOOLS, RIGHT TIME, RIGHT PLACE: TELEHEALTH FOR OPIOID USE DISORDER IN VULNERABLE SETTINGS", aims to increase access to buprenorphine treatment for OUD in settings such as...

The federal Project Grant award, funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Opioid STR (CFDA 93.788) program, provides $400,907,000 to the Ohio Department of Mental Health to address the opioid and stimulant crisis in Ohio. The award will continue the state's efforts to flatten opioid and drug poisoning death rates, increase access to harm reduction, focus on peer recovery supports, expand evidence-based practices, and increase upstream...

This Project Grant award of $193,336 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to evaluate the impact of a pharmacist-integrated model of opioid use disorder (OUD) treatment on increasing naloxone co-prescribing in primary care settings. The key objectives are to: 1) describe federal, state, and clinic-level policies and OUD interventions impacting naloxone co-prescribing at four primary care sites; 2) investigate...